Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies

Leukemia and Lymphoma

Volumn 45, Issue 5, 2004, Pages 937-944

  Robak, Tadeusz ^a   Smolewski, Piotr ^a   Urbanska Rys, Halina ^a   Gora Tybor, Joanna ^a   Blonski, Jerzy Z ^a   Kasznicki, Marek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

2 CdA; B CLL; Cladribine; Combined therapy; Monoclonal antibody; Non Hodgkin's lymphoma; Purine nucleoside analogues; Rituximab

Indexed keywords

ALLOPURINOL; ANTIBODY; BIODRYBIN; BLEOMYCIN; CD20 ANTIBODY; CD20 ANTIGEN; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DIPHENHYDRAMINE; DOXORUBICIN; FLUDARABINE; IMMUNOMODULATING AGENT; MITOXANTRONE; PARACETAMOL; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; B CELL LEUKEMIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG TOXICITY; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; HYPOTENSION; INFECTION; INFLUENZA; LYMPHOPROLIFERATIVE DISEASE; MALE; MORTALITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STATISTICAL ANALYSIS; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 1842588045     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819032000159825     Document Type: Article

References (43)

1. Kosmas, C., Stamatopoulos, K., Stavroyianni, N., Tsavaris, N. and Papadaki, T. (2002) "ANti-CD20-based therapy of B cell lymphoma: state of the art", Leukemia, 16, 2004-2015.
2. Robak, T. (2003) "MOnoclonal antibodies in the treatment of chronic lymphoid leukemias", Leukemia and Lymphoma, 45, 205-220.
3. Huhn, D., von Schilling, C., Wilhelm, M., Hallek, M., Kuse, R., Knauf, W., et al. (2001) "RItuximab therapy of patients with B-cell chronic lymphocytic leukemia", Blood, 98, 1326-1331.
4. Davis, T.A., White, C.A., Grillo-Lopez, A.J., Velasquez, W.S., Link, B., Maloney, D.G., et al. (1999) "SIngle-agent monoclonal antibody efficacy in bulky - non-Hodgkin's lymphoma: Results of a phase II trial of rituximab", Journal of Clinical Oncology, 17, 1851-1857.
5. Coiffier, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D., et al. (1998) "RItuximab (anti-CD20 monoclonal antibody for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study", Blood, 92, 1927-1932.
6. McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., et al. (1998) "RItuximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program", Journal of Clinical Oncology, 16, 2825-2833.
7. Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N. and Bonavida, B. (1997) "CHimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs", Cancer Biotherapy and Radiopharmaceuticals, 12, 177-186.
8. Chow, K.U., Sommerlad, W.D., Boehrer, S., Schneider, B., Seipelt, G., Rummel, M.J., et al. (2002) "ANti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases", Haematologica, 87, 33-43.
9. Alas, S., Bonavida, B. and Emmanouilides, C. (2000) "POtentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab", Anticancer Research, 20, 2961-2966.
10. Di Gaetano, N., Xiao, Y., Erba, E., Bassan, R., Rambaldi, A., Goloy, J., et al. (2001) "SYnergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone", British Journal of Haematology, 114, 800-809.
11. Rummel, M.J., Chow, K.U., Hoelzer, D., Mitrou, P.S. and Weidmann, F. (2002) "IN vitrE studies with bendamustine: enhaced activity in combination with rituximab", Seminars in Oncology, 29 (4 suppl 13), 12-14.
12. Rose, A.L., Smith, B.E. and Maloney, D.G. (2002) "GLucocorticoids and rituximab iS vitro: synergistic direct antiproliferative and apoptotic effects", Blood, 100, 1765-1773.
13. Shan, D., Gopal, A.K. and Press, O.W. (2001) "SYnergistics effects of the fenretidine (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells", Clinical Cancer Research 7, 2490-2495.
14. Robak, T. and Kasznicki, M. (2002) "ALkylating agents and nucleoside analogues in the treatment of B-cell chronic lymphocytic leukemia", Leukemia, 16, 1015-1027.
15. Smolewski, P., Szmigielska, A., Cebula, B., Sobczak, A., Darzynkiewicz, Z. and Robak, T. (2002) "PRo-apoptotic effect of rituximab alone and in combination with purine nucleoside analogues in B-cell chronic lymphocytic leukemia cells measured by fluorochrome labeled inhibitors of caspases (FLICA) assay", Blood, 100 (suppl 1), 387a (abstract 1503).
16. Schulz, H., Klein, S.K., Rehwald, U., Reiser, M., Hinke, A., Knauf, W.U., et al. (2002) "PHase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia", Blood, 100, 3115-3120.
17. Savage, D.G., Cohen, N.S., Hesdorffer, C.S., Heitjan, D., Oster, M.W., Garrett, T.J., et al. (2003) "COmbined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia", Leukemia and Lymphoma, 44, 477-481.
18. Byrd, J.C., Peterson, B.L., Morrison, V.A., Park, K., Jacobson, R., Hoke, E., et al. (2003) "RAndomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALG B9712)", Blood, 101, 6-14.
19. Wierda, W., O'Brien, S., Albitar, M., Lerner, S., Phunkett, W., Giles, F., et al. (2001) "COmbined fludarabine, cyclophosphamide and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia (abstract)", Blood, 98, 77a (Abstract 3210).
20. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S., et al. (1996) "NAtional Cancer Institute Sponsored working group guidelines for chronic lymphocytic leukaemia: Revised guidelines for diagnosis and treatment", Blood, 87, 4990-4997.
21. Harris, N.H., Jaffe, E.S., Diebold, J., Flandvin, G., Muller-Hermelink, H.K., Vardiman, J., et al. (1999) "WOrld Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997", Journal of Clinical Oncology, 17, 8835-3849.
22. Rai, K.R., Sawitsky, A., Cronkite, E.P., Chanana, A.D., Levy, R.N. and Pasternack, B.S. (1975) "CLinical staging of chronic lymphocytic leukemia", Blood, 46, 219-234.
23. Rai, K.R. (1987) A critical analysis of staging in CLL. In: Chronic Lymphocytic Leukemia Recent Progress and Future Direction edited by Gale R.P. and Rai, K.R. New York: Alau R. Liss 253. Pp. 253.
24. Kazimierezuk, Z., Cottan, H.B., Ravauliar, G.R. and Robins, R.K. (1984) "SYnthesis of 2′-deoxynucleosides via a novel direct stereospecific serum salt glycosylation procedure", Journal of American Chemical Society, 106, 6379-6382.
25. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., et al. (1999) "REport of an international workshop to standarize response criteria for non-Hodgkin's lymphomas", Journal of Clinical Oncology 17, 1244-1253.
26. Miller, A.B., Hoogstraten, B., Staquet, M. and Winkler, A. (1981) "REporting results of cancer treatment", Cancer, 47, 207-214.
27. Duffy, D.R. and Santer, T.J. (1987) "COnfidence intervals binomial parameter based on multistage tests", Biometrics, 47, 207-214.
28. Kaplan, E.L. and Meier, P. (1958) "NOnparametric estimation from incomplete observations", J Am Stat Assoc, 53, 457-481.
29. Foran, J.M. (2002) "ANtibody-based therapy of non-Hodgkin's lymphoma", Best Practice and Research in Clinical Hematology, 15, 449-465.
30. Maloney, D.G., Grillo-Lopez, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., et al. (1997) "IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma", Blood, 90, 2188-2195.
31. Buckstein, R.J., Rimric, K., Pennell, N., Spaner, D., Hewitt, K. and Berinstein, N.L. (2001) "PRolonge molecular and clinical remission after treatment of a patient with follicular lymphoma with rituximab", Leukemia and Lymphoma, 41, 451-455.
32. Czuczman, M.S., Fallon, A., Mohr, A., Stewart, C., Bernstein, Z.P., McCarthy, P., et al. (2002) "RItuximab in combination with CHOP or fludarabine in low-grade lymphoma", Seminars in Oncology, 29, 36-40.
33. Hiddemann, W., Dreyling, M., Unterhalt, M. and German low Grade Lymphoma Study Group (2003) "RItuximab plus chemotherapy in follicular and mantle cell lymphomas", Seminars Oncology, 30, suppl 1, 16-20.
34. Howard, O.M., Gribben, J.G., Neuberg, D.S., Grossbard, M., Poor, C., Janicek, M.J., et al. (2002) "RItuximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival", Journal of Clinical Oncology, 20, 1288-1294.
35. Wilson, W.H. (2000) "CHemotherapy sensitization by rituximab: Experimental and clinical evidence", Seminars in Oncology, 27 (suppl 12), 30-36.
36. Robak, T., Göra-Tybor, J., Krykowski, E., Walewski, J.A., Borawska, A., Pluzanska, A., et al. (1997) "ACtivity of 2-chlorodeoxyadenposine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodkin's lymphoma", Leukemia and Lymphoma, 26, 99-105.
37. Robak, T., Blonski, J.Z., Kasznicki, M., Konopka, L., Ceglarek, B., Dmoszynska, A., et al. (2000) "CLadribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients", British Journal of Haematology, 108, 357-368.
38. Robak, T., Gora-Tybor, J., Lech-Maranda, E., Blonski, J.Z. and Kasznicki, M. (2001) "CLadribine in combination with mitoxantrone and cyclophosphamide (CMC) in the treatment of heavily pretreated patients with advanced indolent lymphoid malignancies", European Journal of Haematology, 66, 188-194.
39. PlosAer, G.L. and Figgitt, D.P. (2003) "RItuximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukemia", Drugs, 63, 803-843.
40. Hiddeman, W., Forspointner, R., Fiedler, F., Gramatzki, M., Dorken, B., Illiger, H.J., et al. (2001) "THe addition of rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular and mantle cell lymphomas (MCL) - Results of a prospective randomized comparison of the German Low Grade Study Group (GLSG)", Blood, 98, 844a (abstract 3507).
41. Sacchi, S., Tucci, A., Merli, F., Orsucci, L., Cervetti, G., Occhini, U., et al. (2002) "PHase II study with fludarabine and cyclophosphamide plus rituximab (FC + R) in relapsed follicular lymphoma patients", Blood, 100, suppl 572a (abstract 2246).
42. Polliack, A., Cohen, Y., Daas, N., Libster, D., Shwidel, L., Klepfish, A., et al. (2001) "FLudarabine (FLU)-containing regimen and rituximab (RI) as primary therapy with curative intent for younger patients with progressive and advanced B-CLL: High rate of initial response including molecular remission", Blood, 98, (suppl 1) 364a (abstract 1532).
43. Cohen, A., Polliack, A., Ben-Bassat, I., Avigdor, A., Bennett, M., Berkowicz, M., et al. (2002) "REsults of a phase II study employing a combination of fludarabine, cyclophosphamide and rituximab (FCR) as primary therapy for patients with advanced follicular lymphoma (FL). The Israel cooperative Lymphoma Group", Blood, 100, (suppl. 1) 360a (abstract 1393).